Compare PLAY & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAY | CLLS |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 394.4M |
| IPO Year | 2011 | 2014 |
| Metric | PLAY | CLLS |
|---|---|---|
| Price | $11.32 | $2.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $23.83 | $8.33 |
| AVG Volume (30 Days) | ★ 1.5M | 27.5K |
| Earning Date | 06-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $5.00 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.61 | $1.33 |
| 52 Week High | $35.38 | $5.48 |
| Indicator | PLAY | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 30.97 |
| Support Level | $9.61 | $2.50 |
| Resistance Level | $13.98 | $3.83 |
| Average True Range (ATR) | 0.90 | 0.17 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 29.29 | 10.99 |
Dave & Buster's Entertainment Inc is an owner and operator of entertainment and dining venues in North America that offer experiences for both adults and families under the Dave & Buster's and Main Event brands. The company combines various forms of entertainment, including games, bowling, and watching live sports and other televised events, with a full menu of entrees and appetizers and a selection of alcoholic and non alcoholic beverages, all in one location. Its concept focuses on providing customers the opportunity to Eat, Drink, Play, and Watch, appealing to a balanced mix of adults, families, and teenagers. The company also operates internationally in the early stage as a franchisor of the Dave & Buster's brand.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.